FindTrial
Sign In

A Phase III, Double-Blind, Non-inferiority Study of Favipiravir versus Oseltamivir Phosphate in Patients with Influenza Virus Infection

A Phase III, Double-Blind, Non-inferiority Study of Favipiravir versus Oseltamivir Phosphate in Patients with Influenza Virus Infection

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220902
Enrollment
Unknown
Registered
2009-10-29
Start date
2009-10-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza infection

Interventions

investigational material(s) Generic name etc : T-705a INN of investigational material : Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigational material : oral

Sponsors

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients aged between 20 and 74 - Patients who show a positive reaction to influenza virus antigen using a test kit from nasal or pharyngeal swabs; - Patients with 2 or more of the following symptoms (moderate to severe in severity)

Exclusion criteria

Exclusion criteria: Patients who have had symptoms of influenza (one of the symptoms listed under the inclusion criteria) for 48 hours or more prior to the start of the study.

Design outcomes

Primary

MeasureTime frame
Efficacy and safety Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026